Grace Therapeutics (GRCE) Change in Account Payables (2023 - 2026)
Grace Therapeutics (GRCE) posted Change in Account Payables of $863000.0 for Q1 2026, up 2297.22% sequentially from $36000.0 in Q4 2025, and up 332.61% YoY from $199484.7 in Q1 2025.
Grace Therapeutics (GRCE) Change in Account Payables (2023 - 2026) Analysis & Trends
Grace Therapeutics has reported Change in Account Payables for 4 years, with the latest figure at $863000.0 in Q1 2026.
- Quarterly Change in Account Payables rose 332.61% year-over-year to $863000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $543000.0 (up 746.43% YoY) and the FY2026 annual result came in at $543000.0, up 746.43% from the prior year.
- Change in Account Payables advanced to $863000.0 in Q1 2026 per GRCE's latest filing, from $36000.0 in the prior quarter.
- Over five years, Change in Account Payables peaked at $914000.0 in Q2 2024 and troughed at -$1.4 million in Q2 2023.
- A 4-year average of -$96923.1 and a median of -$61000.0 in 2024 frame the typical range for Change in Account Payables.
- The sharpest annual moves came in 2025 and 2026: Change in Account Payables tumbled 1503.95% in 2025, then soared 332.61% in 2026.
- Over 4 years, Change in Account Payables stood at $395000.0 in 2023, then tumbled by 277.97% to -$703000.0 in 2024, then surged by 105.12% to $36000.0 in 2025, then soared by 2297.22% to $863000.0 in 2026.
- According to Business Quant data, Change in Account Payables over the past three periods registered $863000.0, $36000.0, and -$1.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Grace Therapeutics | 37.99 Mn | 37.99 Mn | - | -897,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -897,000.00 |
| Jun 30, 2026 | -897,000.00 |
| Mar 31, 2026 | 863,000.00 |
| Mar 31, 2026 | 863,000.00 |
| Dec 31, 2025 | 36,000.00 |
| Dec 31, 2025 | 36,000.00 |
| Sep 30, 2025 | -1.07 Mn |
| Sep 30, 2025 | -1.07 Mn |
| Jun 30, 2025 | 711,000.00 |
| Jun 30, 2025 | 711,000.00 |
| Mar 31, 2025 | -371,000.00 |
| Mar 31, 2025 | -371,000.00 |
| Dec 31, 2024 | -703,000.00 |
| Dec 31, 2024 | -703,000.00 |
| Sep 30, 2024 | 76,000.00 |
| Sep 30, 2024 | 76,000.00 |
| Jun 30, 2024 | 914,000.00 |
| Jun 30, 2024 | 914,000.00 |
| Mar 31, 2024 | -61,000.00 |
| Mar 31, 2024 | -61,000.00 |